Skip to main content
SpringerLink
Log in

Assessment of the Effects of Glycosylation on the Pattern and Kinetics of Degradation of Lenograstim in Comparison to Filgrastim Using a Stability-Indicating Orthogonal Testing Protocol

  • Original
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

In the biopharmaceutical industry, protein aggregation and/or degradation has profound pathological implications and is encountered routinely during production, shipping, storage and administration. Lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) was subjected to stress conditions, namely, oxidation, pH, temperature, agitation and repeated freeze–thaw to generate all possible degradation products. An orthogonal stability-indicating testing protocol (RP-HPLC, SE-HPLC, ELISA and SDS-PAGE) was developed and validated for assessment of the pattern and kinetics of aggregation/degradation, under the studied experimental conditions. Results indicated clearly that Lenograstim is susceptible to degradation induced by the studied stress conditions. However, Lenograstim was found relatively more stable than Filgrastim (non-glycosylated recombinant human granulocyte colony-stimulating factor) which was attributed to the effect of glycosylation. Oxidized forms and high molecular weight aggregates of Lenograstim and Filgrastim were detected in all samples subjected to stress conditions to different degrees. ELISA assay and SDS-PAGE results were generally in agreement to those obtained using SE-HPLC assay which confirmed its selectivity to the intact drug. However, formation of soluble aggregates of both drugs was found to occur via physical adsorption and formation of intermolecular disulfide bonds. Results confirmed the need for an orthogonal testing protocol since it was impossible to reveal all types of degradation products using a single technique. Results raised a concern about the efficacy and safety of such sensitive products and highlighted the need for simple tools to inspect biologics for soluble aggregates and sub-visible particles before administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wang W (1999) Int J Pharm 185:129–188

    Article  CAS  Google Scholar 

  2. Ceaglio N, Etcheverrigaray M, Kratje R, Oggero M (2010) Biochimie 92:971–978

    Article  CAS  Google Scholar 

  3. Wang W (2005) Int J Pharm 289:1–30

    Article  CAS  Google Scholar 

  4. Chi EY, Krishnan S, Kendrick BS, Chang BS, Carpenter JF, Randolph TW (2003) Protein Sci 12:903–913

    Article  CAS  Google Scholar 

  5. Mazola Y, Chinea G, Musacchio A (2011) PLoS Comput Biol 7:1–7

    Article  Google Scholar 

  6. Oberg F, Sjohamn J, Fischer G, Moberg A, Pedersen A, Neutze R, Hedfalk K (2011) J Biol Chem 286:31915–31923

    Article  Google Scholar 

  7. Sola RJ, Griebenow K (2009) J Pharm Sci 98:1223–1245

    Article  CAS  Google Scholar 

  8. Sola RJ, Griebenow K (2010) BioDrugs 24:9–21

    Article  CAS  Google Scholar 

  9. Herman AC, Boone TC, Lu HS (1996) Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. In: Pearlman R, Wang YJ (eds) Formulation, characterization, and stability of protein drugs. Plenum Pres, New York, pp 303–328

    Google Scholar 

  10. Batkovska-Borozanova I, Tonic-Ribarska J, Trajkovic-Jolevska S (2011) Webmed Central 11:pp 1–5. https://www.webmedcentral.com/wmcpdf/Article_WMC001117.pdf

  11. Shaltout EL, Al-Ghobashy MA, Fathalla FA, Salem MY (2014) J Pharm Biomed Anal 97:72–80

    Article  CAS  Google Scholar 

  12. Piedmonte DM, Treuheit MJ (2008) Adv Drug Deliv Rev 60:50–58

    Article  CAS  Google Scholar 

  13. ICH guidelines: Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products (1995), http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf

  14. Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, H-c Mahler, Jiskoot W (2012) J Pharm Sci 101:895–913

    Article  CAS  Google Scholar 

  15. Abed HS, Al-Ghobashy MA, Fathalla FA, Salem MY (2014) Chromatographia 77:1–9

    Article  Google Scholar 

  16. Skrlin A, Krnic EK, Gosak D, Prester B, Mrsa V, Vuletic M, Runac D (2010) J Pharm Biomed Anal 53:262–268

    Article  CAS  Google Scholar 

  17. Raso SW, Abel J, Barnes JM, Maloney KM, Pipes G, Treuheit MJ, King J, Brems DN (2005) Protein Sci 14:2246–2257

    Article  CAS  Google Scholar 

  18. Skrlin A, Radic I, Vuletic M, Schwinke D, Runac D, Kusalic T, Paskvan I, Krsic M, Bratos M, Marinc S (2010) Biologicals 38:557–566

    Article  CAS  Google Scholar 

  19. Faraji F, Mofid MR, Babaeipour V, Divsalar A, Dehaghani SA (2010) Int J Env Sci Dev 1:15–19. http://www.ijesd.org/papers/4-B024.pdf

  20. Tonic-Ribarska J, Trajkovic-Jolevska S, Brezovska K, Dimitrovska A (2008) RP-HPLC method for determination of Lenograstim (rHuG-CSF) in pharmaceutical formulation. 7th Central European Symposium on Pharmaceutical Technology and Biodelivery Systems Pharm. J. Slovenia, Slovenia, pp 122–124

    Google Scholar 

  21. Ribarska J, Jolevska S, Panovska A, Dimitrovska A (2008) Acta Pharm. 58:199–206

    Article  CAS  Google Scholar 

  22. Tonic-Ribarska J, Brezovska K, Trajkovic-Jolevska S (2009) J Liq Chrom Rel Technol 32:2545–2555

    Article  CAS  Google Scholar 

  23. Jain D, Basniwal PK (2013) J Pharm Biomed Anal 86:11–35

    Article  CAS  Google Scholar 

  24. ICH Guidelines: Q2(R1): Validation of analytical procedures (2005) http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf

  25. The United States Pharmacopoeia and National Formulary, US Pharmacopoeial Convention Inc., USA (2011)

  26. The European Pharmacopoeia (2010) Filgrastim concentrated solution. The Council of Europe, France

    Google Scholar 

  27. Human G-CSF Quantikine ELISA-component kit (http://www.rndsystems.com/pdf/dcs50.pdf)

  28. Laemmli UK (1970) Nature 277:680–685

    Article  Google Scholar 

  29. Reubsaet JLE, Beijnen JH, Bult A, Hop E, Scholten SD, Teeuwsen J, Underberg WJM (1998) J Pharm Biomed Anal 17:283–289

    Article  CAS  Google Scholar 

  30. Yin J, Chu J-W, Ricci MS, Brems DN, Wang DIC, Trout BL (2005) Pharm Res 22:141–147

    Article  CAS  Google Scholar 

  31. Strambini GB, Gabellieri E (1996) Biophys J 70:971

    Article  CAS  Google Scholar 

  32. Eckhardt BM, Oeswein JQ, Bewley TA (1991) Pharm Res 8:1360–1364

    Article  CAS  Google Scholar 

  33. Wang W, Nema S, Teagarden D (2010) Int J Pharm 390:89–99

    Article  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Dr. Ashraf Elhadary, SEDICO Pharmaceuticals, Egypt for his help and technical assistance with the chromatographic measurements.

Author information

Authors and Affiliations

  1. National Organization for Research and Control of Biologicals, Giza, Egypt

    Lamiaa A. Hassan & Faten A. Fathalla

  2. Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt

    Medhat A. Al-Ghobashy & Samah S. Abbas

  3. Bioanalysis Research Group, Faculty of Pharmacy, Cairo University, Cairo, Egypt

    Medhat A. Al-Ghobashy

Authors
  1. Lamiaa A. Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Medhat A. Al-Ghobashy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faten A. Fathalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samah S. Abbas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Medhat A. Al-Ghobashy.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 1093 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, L.A., Al-Ghobashy, M.A., Fathalla, F.A. et al. Assessment of the Effects of Glycosylation on the Pattern and Kinetics of Degradation of Lenograstim in Comparison to Filgrastim Using a Stability-Indicating Orthogonal Testing Protocol. Chromatographia 78, 1005–1015 (2015). https://doi.org/10.1007/s10337-015-2910-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10337-015-2910-2

Keywords

Search

Navigation